- Bristol-Myers Squibb (NYSE:BMY) inks an agreement with Osaka, Japan-based Ono Pharmaceutical securing exclusive rights to develop, manufacture and commercialize ONO-4578 worldwide except Japan, South Korea,Taiwan, China and ASEAN countries.
- The companies will partner on development and commercialization in Japan, South Korea and Taiwan while Ono will retain exclusive rights in China and ASEAN countries.
- Under the terms of the agreement, BMY will pay $40M upfront, milestones and royalties on net sales.
- ONO-4578 is an orally available, selective antagonist of EP4, a Prostaglandin E2 (PGE2) receptor. PGE2 is an immunosuppressive factor in the tumor microenvironment which promotes tumor progression. Controlling PGE2 via a PGE2 receptor antagonist may enhance the effectiveness of immuno-oncology therapies like Opdivo (nivolumab) and Yervoy (ipilimumab).
- Now read: Biotech Analysis Central: Daily Pharma News - October 17, 2017
Original article